RISK FACTORS FOR HYPERSENSITIVITY REACTIONS (HSRS) AMONG OVARIAN CANCER (EOC) PATIENTS TREATED WITH CARBOPLATIN-BASED CHEMOTHERAPY

被引：0
|
作者：
Jerzak, K. [1 ]
Manshadi, S. Deghan [1 ]
Ng, P. [2 ]
Maganti, M. [2 ]
McCuaig, J. M. [2 ]
Oza, A. [2 ]
Mackay, H. [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-0974
引用
收藏
页码：331 / 332
页数：2
相关论文
共 50 条
  • [31] The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
    Wu, Xia
    Feng, Qin-Mei
    Wang, Ying
    Shi, Jun
    Ge, Hai-Liang
    Di, Wen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 279 - 291
  • [32] PLATINUM RE-CHALLENGE IN OVARIAN CANCER PATIENTS WITH CARBOPLATIN-ASSOCIATED HYPERSENSITIVITY REACTIONS
    Narui, C.
    Tanabe, H.
    Takakura, S.
    Nagayoshi, Y.
    Komazaki, H.
    Maruta, T.
    Inoue, M.
    Takano, H.
    Isonishi, S.
    Ochiai, K.
    Sasaki, H.
    Okamoto, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 520 - 520
  • [33] Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin
    Narui, Chikage
    Tanabe, Hiroshi
    Shapiro, Jason S.
    Nagayoshi, Yoko
    Maruta, Takenori
    Inoue, Momoko
    Hirata, Yukihiro
    Komazaki, Hiromi
    Takano, Hirokuni
    Niimi, Shigeki
    Isonishi, Seiji
    Okamoto, Aikou
    IN VIVO, 2019, 33 (06): : 2045 - 2050
  • [34] Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative Oncology Group study
    Dimopoulos, MA
    Papadopoulou, M
    Andreopoulou, E
    Papadimitriou, C
    Pavlidis, N
    Aravantinos, G
    Aspropotamitis, A
    Anagnostopoulos, A
    Fountzilas, G
    Michalas, S
    Pectacides, D
    GYNECOLOGIC ONCOLOGY, 1998, 70 (01) : 70 - 74
  • [35] Relationship between thrombocytopenia and survival of patients with epithelial ovarian cancer (EOC) who received paclitaxel and carboplatin chemotherapy.
    Nagao, S
    Fujiwara, K
    Imafuku, N
    Kozuka, Y
    Kagawa, R
    Oda, T
    Maehata, K
    Ishikawa, H
    Koike, H
    Kohno, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 466S - 466S
  • [36] Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
    Pignata, Sandro
    Lorusso, Domenica
    Joly, Florence
    Gallo, Ciro
    Colombo, Nicoletta
    Sessa, Cristiana
    Bamias, Aristotelis
    Salutari, Vanda
    Selle, Frederic
    Frezzini, Simona
    De Giorgi, Ugo
    Pautier, Patricia
    Bologna, Alessandra
    Orditura, Michele
    Dubot, Coraline
    Gadducci, Angiolo
    Mammoliti, Serafina
    Ray-Coquard, Isabelle
    Zafarana, Elena
    Breda, Enrico
    Favier, Laure
    Ardizzoia, Antonio
    Cinieri, Saverio
    Largillier, Remy
    Sambataro, Daniela
    Guardiola, Emmanuel
    Lauria, Rossella
    Pisano, Carmela
    Raspagliesi, Francesco
    Scambia, Giovanni
    Daniele, Gennaro
    Perrone, Francesco
    LANCET ONCOLOGY, 2021, 22 (02): : 267 - 276
  • [37] Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
    Ito, Yasuhiro
    Karayama, Masato
    Inui, Naoki
    Kuroishi, Shigeki
    Nakano, Hideki
    Nakamura, Yutaro
    Yokomura, Koshi
    Toyoshima, Mikio
    Shirai, Toshihiro
    Masuda, Masafumi
    Yamada, Takashi
    Yasuda, Kazumasa
    Hayakawa, Hiroshi
    Suda, Takafumi
    Chida, Kingo
    LUNG CANCER, 2014, 84 (03) : 259 - 264
  • [38] CONSOLIDATION RADIOTHERAPY FOLLOWING CARBOPLATIN-BASED CHEMOTHERAPY IN RADICALLY OPERATED ADVANCED OVARIAN-CANCER - A PILOT-STUDY
    PICKEL, H
    PETRU, E
    LAHOUSEN, M
    STETTNER, H
    HEYDARFADAI, M
    ARIANSCHAD, K
    HACKL, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (03): : 184 - 187
  • [39] Second cancer (SCa) risk among patients (pt) treated with abdomino-pelvic radiation (XRT) for epithelial ovarian cancer (EOC).
    Kumar, Aalok
    Nhu Le
    Gilks, Cyril Blake
    Santos, Jennifer
    Holloway, Caroline
    Tinker, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
    De Boo, L.
    Cimino-Mathews, A.
    Lubeck, Y.
    Daletzakis, A.
    Opdam, M.
    Sanders, J.
    Hooijberg, E.
    van Rossum, A. G. J.
    Loncova, Z.
    Rieder, D.
    Trajanoski, Z.
    Vollebergh, M.
    Sobral-Leite, M.
    Van de Vijver, K.
    Broeks, A.
    van der Wiel, R.
    van Tinteren, H.
    Linn, S. C.
    Horlings, H.
    Kok, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345